You just read:

CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer

News provided by

CASI Pharmaceuticals, Inc.

Apr 14, 2017, 07:00 ET